Organogenesis Holdings Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing was signed March 1, 2023. Organogenesis develops, manufactures and sells regenerative-medicine products in Advanced Wound Care and Surgical & Sports Medicine; substantially all revenue is generated in the United States.
Financial results
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $450.9 million | $467.4 million | Down 4% |
| Gross profit / margin | $345.9 million / 76.7% | $353.2 million / 75.6% | Gross profit down 2% |
| Operating expenses | $323.6 million | $280.9 million | Up 15% |
| Operating income / margin | $22.3 million / 4.9% | $72.2 million / 15.5% | Down 69% |
| Net income / margin | $15.5 million / 3.4% | $94.2 million / 20.2% | Down 83% |
| Cash from operations | $24.9 million | $62.0 million | Down $37.1 million |
| Capital expenditures | $33.9 million | $31.2 million | Up $2.7 million |
2021 net income included a $48.3 million income-tax benefit from releasing a valuation allowance; 2022 included $4.8 million of income-tax expense. Adjusted EBITDA, a non-GAAP measure, was $49.3 million in 2022 versus $89.1 million in 2021.
At year-end, cash and cash equivalents were $102.5 million, working capital was $147.6 million, and total assets were $449.4 million. Term-loan principal was $71.3 million; no revolving borrowings were outstanding, with $125 million available subject to credit-agreement covenants. The company reported covenant compliance at December 31, 2022 and expected available liquidity and operating cash flows to fund operations, capital spending and debt service for at least 12 months beyond filing.
Business and changes from the prior year
- Advanced Wound Care revenue was $422.2 million, down 2%; Surgical & Sports Medicine revenue was $28.7 million, down 23%.
- PuraPly revenue increased to $242.7 million from $198.1 million. Management attributed growth to expanded sales coverage, sites of care and adoption of product line extensions.
- Overall revenue fell despite PuraPly growth, primarily because of lower sales of certain other wound-care products, a GPO settlement fee recorded as a revenue reduction, and the continued impact of suspending ReNu and NuCel commercialization in 2021.
- Dermagraft manufacturing was suspended in late 2021 and sales in the second quarter of 2022. The company plans to resume supply through a new facility or third-party manufacturer; management expects customers to substitute Apligraf, but that outcome is uncertain.
- Gross margin improved, which management attributed partly to a shift toward higher-margin products. Operating expenses rose, including higher sales-force headcount, travel and marketing, legal and consulting costs, and research and development spending.
Outlook, risks and unusual items
- No quantified revenue, earnings or cash-flow guidance is provided. Management’s strategy emphasizes growing wound-care penetration, expanding in Surgical & Sports Medicine, developing products and clinical evidence, and selectively pursuing acquisitions.
- ReNu remains in Phase 3 development for knee osteoarthritis; commercial distribution was suspended in 2021 pending the regulatory pathway. The filing describes regulatory approval and clinical-trial outcomes as uncertain.
- Reimbursement is a central risk. CMS could revisit separate payment for skin substitutes; draft local coverage policies proposed noncoverage or use limits for PuraPly products. Commercial-payer coverage is also limited for several products. A federal rebate for discarded single-use product took effect January 1, 2023; any liability was not yet known and could be material.
- The company restated 2021 and first-quarter 2022 figures for an immaterial error related to previously disputed GPO fees. The settlement was $3.3 million; $2.6 million was recorded as a 2022 earnings charge and $0.7 million reduced opening 2021 equity. The filing states prior-period misstatements were not material.
- Management and the auditor concluded that material weaknesses in internal control over financial reporting remained at year-end, involving identification and assessment of significant non-routine transactions, IT general controls and segregation of duties. Disclosure controls were also deemed ineffective. An ERP implementation was delayed, with go-live anticipated in 2023.
- A securities class action filed in 2021 alleges misleading statements concerning revenue, sales growth and competition related to Affinity and PuraPly XT. The company disputes the claims and intends to seek dismissal; the case was in an early stage.
- Subsequent to year-end, the company announced a reduction of 70 employees, approximately 7% of headcount, and expected about $1.7 million of first-quarter 2023 severance charges. It also paused a manufacturing-facility construction project amid inflation and market conditions, recording $4.2 million for equipment disposal and $0.6 million of cancellation fees in 2022.
Important facts for investors to verify
- Whether revenue stabilizes and growth in PuraPly can offset declines in other products and the loss of ReNu and NuCel sales.
- Dermagraft’s manufacturing restart timeline, cost savings and customer substitution assumptions.
- Final CMS and MAC reimbursement policies, commercial-payer coverage, and the amount of any discarded-product rebate liability.
- Progress and testing evidence for remediation of the disclosed material weaknesses, including ERP implementation.
- ReNu Phase 3 results and the FDA pathway, as well as the status and potential exposure of the securities litigation.
- Cash conversion, capital spending and debt service relative to the company’s liquidity assessment and credit-agreement covenants.